Free Trial

Apollomics (APLM) Competitors

$0.21
-0.02 (-8.75%)
(As of 07/19/2024 ET)

APLM vs. CNTB, ALRN, VTVT, OVID, SLS, VHAQ, THTX, RMTI, ANEB, and ELDN

Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Connect Biopharma (CNTB), Aileron Therapeutics (ALRN), vTv Therapeutics (VTVT), Ovid Therapeutics (OVID), SELLAS Life Sciences Group (SLS), Viveon Health Acquisition (VHAQ), Theratechnologies (THTX), Rockwell Medical (RMTI), Anebulo Pharmaceuticals (ANEB), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical preparations" industry.

Apollomics vs.

Apollomics (NASDAQ:APLM) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.

Connect Biopharma received 13 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 70.83% of users gave Connect Biopharma an outperform vote.

CompanyUnderperformOutperform
ApollomicsOutperform Votes
4
80.00%
Underperform Votes
1
20.00%
Connect BiopharmaOutperform Votes
17
70.83%
Underperform Votes
7
29.17%

Connect Biopharma has lower revenue, but higher earnings than Apollomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$1.22M15.30-$172.60MN/AN/A
Connect BiopharmaN/AN/A-$59.50MN/AN/A

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Connect Biopharma N/A N/A N/A

Apollomics currently has a consensus target price of $2.00, suggesting a potential upside of 852.38%. Connect Biopharma has a consensus target price of $6.50, suggesting a potential upside of 420.00%. Given Apollomics' higher probable upside, analysts clearly believe Apollomics is more favorable than Connect Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollomics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Connect Biopharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Apollomics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500.

In the previous week, Apollomics had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 2 mentions for Apollomics and 0 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.84 beat Apollomics' score of 0.48 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Neutral
Connect Biopharma Very Positive

Summary

Connect Biopharma beats Apollomics on 6 of the 11 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLM vs. The Competition

MetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$18.66M$7.05B$5.22B$8.42B
Dividend YieldN/A2.67%2.80%3.94%
P/E RatioN/A12.39134.2016.20
Price / Sales15.30310.772,179.3082.77
Price / CashN/A32.7535.7034.86
Price / Book0.435.734.854.46
Net Income-$172.60M$146.45M$110.49M$215.77M
7 Day Performance6.60%-2.37%-0.61%0.08%
1 Month Performance1.46%6.26%6.97%5.51%
1 Year Performance-96.42%-4.74%3.80%0.05%

Apollomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNTB
Connect Biopharma
3.2981 of 5 stars
3.30 / 5 stars
$1.25
-1.6%
$6.50
+420.0%
+12.4%$68.88MN/A0.0081Positive News
ALRN
Aileron Therapeutics
2.4948 of 5 stars
2.49 / 5 stars
$3.18
+2.9%
$19.00
+497.5%
+50.9%$68.72MN/A-1.0015Positive News
VTVT
vTv Therapeutics
0 of 5 stars
0.00 / 5 stars
$22.51
+9.9%
N/A-29.2%$67.76M$1M-2.5516News Coverage
Gap Down
OVID
Ovid Therapeutics
4.8932 of 5 stars
4.89 / 5 stars
$0.95
+0.5%
$4.70
+393.0%
-70.5%$67.64M$473,695.00-1.3140Gap Up
SLS
SELLAS Life Sciences Group
0.9278 of 5 stars
0.93 / 5 stars
$1.16
+0.9%
$3.00
+158.6%
-36.6%$67.00M$1M-1.0510Options Volume
News Coverage
VHAQ
Viveon Health Acquisition
0 of 5 stars
0.00 / 5 stars
$10.00
flat
N/AN/A$66.49MN/A0.00N/A
THTX
Theratechnologies
0 of 5 stars
0.00 / 5 stars
$1.44
-1.0%
N/A-50.9%$65.98M$81.76M-7.55103Positive News
RMTI
Rockwell Medical
3.6348 of 5 stars
3.63 / 5 stars
$2.13
+0.9%
$7.00
+228.6%
-56.2%$64.58M$83.61M-5.92237Positive News
ANEB
Anebulo Pharmaceuticals
2.0905 of 5 stars
2.09 / 5 stars
$2.47
+8.8%
$6.67
+169.9%
-7.6%$64.05MN/A-6.682Positive News
ELDN
Eledon Pharmaceuticals
2.1059 of 5 stars
2.11 / 5 stars
$2.54
+2.8%
$11.67
+359.3%
+97.1%$63.02MN/A-1.8420Positive News

Related Companies and Tools

This page (NASDAQ:APLM) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners